Evidence map›Paper›PMID 38752311›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Impact of Intrapartum Azithromycin on the Carriage and Antibiotic Resistance of Escherichia coli and Klebsiella pneumoniae in Mothers and Their Newborns: A Substudy of a Randomized, Double-Blind Trial Conducted in The Gambia and Burkina Faso.

Pauline Getanda, Isatou Jagne, Joel D Bognini, Bully Camara, Bakary Sanyang, Saffiatou Darboe, Ellen Sambou, Momodou Barry, Kady Kassibo, Aminata Cham and 11 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03199547 (Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03199547 phase3completednot on this map

Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2017 to 2021Enrolled11,985ConditionsNeonatal SEPSISArmsAzithromycin, Placebo Oral Tablet
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Pauline GetandaDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Isatou JagneDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Joel D BogniniClinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
Bully CamaraDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Bakary SanyangDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Saffiatou DarboeDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Ellen SambouDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Momodou BarryDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Kady KassiboDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Aminata ChamDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Harriet MendyDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Bintou K J SingatehDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Ebrahim NdureDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Toussaint RouambaClinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
Abdoulie BojangDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Christian BottomleyFaculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Benjamin P HowdenMicrobiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-0237-1473
Umberto D'AlessandroDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.
Halidou TintoClinical Research Unit of Nanoro, Institut de Recherche en Sciences de la Santé, Nanoro, Burkina Faso.
Anna RocaDisease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine (MRCG @ LSHTM), Banjul, The Gambia.ORCID 0000-0001-6034-1868
PregnAnZI-2 Carriage Study Group

Funding

Gates Foundation INV-000253Joint Global Health Trial Scheme MC_EX_MR/P006949/1Medical Research CouncilUKRI
6 · The paper itself

Abstract

backgroundLimited data exist on the effects of intrapartum azithromycin on the prevalence of carriage and antibiotic resistance of Enterobacterales.

methodsWe conducted a randomized trial in The Gambia and Burkina Faso where women received intrapartum azithromycin (2 g) or placebo. We determined the impact of treatment on the prevalence of carriage and antibiotic resistance of Escherichia coli and Klebsiella pneumoniae by analyzing rectal swabs (RS), nasopharyngeal swabs (NPS), breast milk, and rectovaginal swabs (RVS). Bacteria were isolated microbiologically; antibiotic susceptibility was confirmed with an E-test. Prevalence ratios (PRs) with 95% confidence intervals (CIs) were used for comparison between arms.

resultsIn infants, E. coli carriage in RS was lower in the intervention than in the placebo arm at day 6 (63.0% vs 75.2%; PR, 0.84; 95% CI, .75-.95) and day 28 (52.7% vs 70.4%; 0.75; 0.64-0.87) post-intervention. Prevalence of azithromycin-resistant E. coli was higher in the azithromycin arm at day 6 (13.4% vs 3.6%; 3.75; 1.83-7.69) and day 28 (16.4% vs 9.6%; 1.71; 1.05-2.79). For K. pneumoniae, carriage in RS was higher in the intervention than in the placebo arm at day 6 (49.6% vs 37.2%, 1.33; 1.08-1.64) and day 28 (53.6% vs 32.9%, 1.63; 1.31-2.03). Prevalence of azithromycin-resistant K. pneumoniae was higher in the azithromycin arm at day 28 (7.3% vs 2.1%; 3.49; 1.30-9.37). No differences were observed for other sample types.

conclusionsIntrapartum azithromycin decreased E. coli carriage but increased both K. pneumoniae carriage and azithromycin resistance in both bacteria. These data need to be considered together with efficacy results to balance the potential short- and long-term impact of the intervention. Clinical Trials Registration.  www.clinicaltrials.gov: NCT03199547.

Indexed as

Anti-Bacterial AgentsAzithromycinCarrier StateEscherichia coliEscherichia coli InfectionsKlebsiella InfectionsKlebsiella pneumoniaeAdultBurkina FasoDouble-Blind MethodDrug Resistance, BacterialFemaleGambiaHumansInfant, NewbornMothersAnti-Bacterial AgentsAzithromycinantibiotic resistancebacterial carriageEscherichia coliintrapartum azithromycinKlebsiella pneumoniae

Identifiers

PMID38752311
PMCPMC11650870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.